

		Intervention:	Biological: MAGE-3.A1 peptide and CpG 7909
930	Recruiting	A Phase I Clinical Trial of an HPV Therapeutic Vaccine	
		Condition:	Human Papillomavirus
		Intervention:	Biological: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
931	Recruiting	Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia	
		Condition:	Cervical Cancer
		Intervention:	
932	Enrolling by invitation	Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials	
		Conditions:	Non-Small Cell Lung Cancer; Multiple Myeloma
		Interventions:	Biological: L-BLP25; Other: No intervention
933	Recruiting	Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer	
		Condition:	Prostatic Neoplasms
		Interventions:	Drug: CT-011 (Anti-PD1 Antibody); Other: Sipuleucel-T (provenge); Drug: Cyclophosphamide
934	Unknown †	Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma	
		Conditions:	Intraocular Melanoma; Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological:
935	Recruiting	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	
		Condition:	Brain and Central Nervous System Tumors
		Interventions:	Biological: carcinoembryonic antigen-expressing measles virus; Genetic: fluorescence in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other:
936	Suspended	Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma	
		Condition:	Metastatic Melanoma
		Intervention:	Biological: Vaccination with RNA-transfected mature autologous DC
937	Completed	Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: incomplete Freund's adjuvant; Biological: sargramostim; Biological: tyrosinase peptide; Biological: tyrosinase-related protein-1
938	Completed	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: incomplete Freund's adjuvant; Biological: recombinant tyrosinase-related
939	Completed	Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: recombinant fowlpox-tyrosinase vaccine; Biological: vaccinia-tyrosinase
940	Completed	Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant
941	Completed	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant
942	Completed	Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic	
		Conditions:	Graft vs Host Disease; Multiple Myeloma

		Interventions:	Drug: Myeloma Immunoglobulin Idiotypic Vaccine-KLH; Drug: GM-CSF
943	Terminated	Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and	
		Condition:	Non-Hodgkin's Lymphoma
		Intervention:	Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine
944	Unknown †	Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia	
		Condition:	Leukemia
		Interventions:	Biological: bcr-abl p210-b3a2 breakpoint-derived multi-peptide vaccine; Biological: sargramostim
945	Withdrawn	Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults	
		Conditions:	Cervical Cancer; Precancerous Condition
		Intervention:	Other: survey administration
946	Completed	Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant
947	Completed	Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission	
		Condition:	Acute Myeloid Leukemia (AML)
		Intervention:	Biological: injection of antigen-loaded cultured dendritic cells
948	Unknown †	Survey of Predictors of Human Papillomavirus (HPV) Vaccination Among Parents of Rural Adolescent Girls in Mysore, India	
		Conditions:	Human Papillomavirus; Cervical Cancer
		Intervention:	
949	Completed	Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: NY-ESO-1 peptide vaccine; Biological: aldesleukin
950	Completed	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: fowlpox virus vaccine vector; Biological: gp100 antigen
951	Recruiting	Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: keyhole limpet hemocyanin; Biological: recombinant MAGE-3.1 antigen;
952	Completed	A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma	
		Conditions:	Lymphoma, Follicular; Lymphoma, Small Lymphocytic
		Intervention:	Drug: autologous human tumor-derived HSPPC-96
953	Terminated	Vaccine Therapy in Treating Patients With Melanoma of the Eye	
		Condition:	Intraocular Melanoma
		Interventions:	Biological: MART-1 antigen; Biological: NA17-A antigen; Biological: gp100 antigen; Biological: tyrosinase
954	Unknown †	Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	
		Condition:	Bladder Cancer
		Intervention:	Biological: MPHOSPH1 and DEPDC1
955	Completed	Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer	
		Condition:	Esophageal Cancer

		Intervention:	Biological: IMF-001
956	Completed Has	Dose Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-	
		Conditions:	Papillomavirus Infections; Genital Diseases, Female
		Interventions:	Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20; Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40; Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP
957	Unknown †	Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients	
		Conditions:	HIV-1 Infection; Cancer; Immunosuppression
		Intervention:	Other: serologic testing
958	Completed	Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients	
		Condition:	Melanoma
		Interventions:	Biological: Melan-A; Other: Melan-A plus Dacarbazine
959	Active, not recruiting	Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer	
		Conditions:	PRAME-positive; Melanoma; Metastatic Melanoma
		Intervention:	Biological: Immunotherapeutic GSK2302025A, different formulations
960	Terminated	Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer	
		Condition:	Prostatic Neoplasms
		Intervention:	Biological: MVA-MUC1-IL2
961	Completed	Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: gp100 antigen; Biological: sargramostim
962	Completed	A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With HM Receiving	
		Condition:	Herpes Zoster
		Intervention:	Biological: V212
963	Completed	Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer	
		Condition:	Carcinoma, Renal Cell
		Intervention:	Drug: Allogeneic DCs and Autologous RCC Tumor Derived Cells
964	Unknown †	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: dendritic cell-gp100-MART-1 antigen vaccine
965	Unknown †	Phase I / II Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer	
		Condition:	Esophageal Cancer
		Intervention:	Biological: URLC10-177, TTK-567, CpG-7909
966	Not yet recruiting	HPV Vaccine Acceptability Among Young Men Who Have Sex With Men	
		Conditions:	HPV Vaccine Attitudes; HPV Vaccine Intention
		Intervention:	
967	Completed	Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous	
		Conditions:	Acute Myelogenous Leukemia; Myelodysplasia
		Intervention:	Biological: autologous tumor cells

968	Unknown †	Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma	
		Condition:	Non-Hodgkin's Lymphoma
969	Active, not recruiting Has	Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma	
		Condition:	Multiple Myeloma
970	Active, not recruiting	Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100	
		Interventions:	Drug: Myeloma Immunoglobulin Idiotype Vaccine; Drug: Bortezomib; Drug: Cyclophosphamide; Drug:
971	Unknown †	Vaccine Therapy in Treating Patients With Metastatic Melanoma	
		Interventions:	Biological: filgrastim; Biological: therapeutic autologous dendritic cells
972	Completed	Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults	
		Intervention:	Biological: HPV 16/18 VLP AS04
973	Recruiting	Study of DC Vaccination Against Glioblastoma	
		Interventions:	Procedure: Surgery; Drug: Chemotherapy; Radiation: Radiotherapy; Biological: DC vaccination; Drug: blank
974	Not yet recruiting	Immunogenicity and Safety of HPV Vaccine in HIV-infected Pre-adolescent Girls and Boys in Kenya	
		Intervention:	Biological: Gardasil vaccine
975	Not yet recruiting	Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens	
		Intervention:	Biological: PEP-CMV
976	Completed	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Colon Cancer	
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological: therapeutic autologous lymphocytes; Drug: chemotherapy; Procedure: surgical procedure
977	Completed	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer	
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological:
978	Completed	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Kidney Cancer	
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological: therapeutic autologous lymphocytes; Procedure: surgical procedure
979	Completed	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Lung Cancer	
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological: therapeutic autologous lymphocytes; Drug: chemotherapy; Procedure: surgical procedure
980	Completed	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Breast Cancer	

		Condition:	Breast Cancer
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological:
981	Unknown †	Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure	
		Conditions:	Carcinoma, Transitional Cell; Bladder Neoplasms
		Intervention:	Biological: Oncolytic adenovirus (serotype 5) - CG0070
982	Completed	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or	
		Condition:	Brain and Central Nervous System Tumors
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological:
983	Completed	Study of gp75 Vaccine in Patients With Stage III and IV Melanoma	
		Condition:	Malignant Melanoma
		Intervention:	Biological: gp75 DNA vaccine
984	Unknown †	PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen	
		Condition:	Pancreatic Cancer
		Intervention:	Biological: PANVAC™-VF
985	Withdrawn	Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia	
		Condition:	Chronic Lymphocytic Leukemia
		Interventions:	Biological: Influenza Vaccine Trivalent Inactivated (TIV); Drug: Pegylated interferon (PEGrIFN- α , Pegasys); Drug:
986	Unknown †	Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx	
		Condition:	Precancerous Condition
		Intervention:	Biological: autologous tumor cell vaccine
987	Unknown †	Biological Therapy in Treating Patients With Glioblastoma Multiforme	
		Condition:	Brain and Central Nervous System Tumors
		Interventions:	Biological: autologous tumor cell vaccine; Biological: sargramostim; Biological: tumor-draining lymph node lymphocyte therapy; Drug: cyclophosphamide; Procedure: conventional surgery
988	Recruiting	Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children	
		Conditions:	Cervical Neoplasia; Human Papillomavirus (HPV) Type 16/18 Infections
		Interventions:	Biological: Cervarix; Biological: MMR; Biological: DTPa
989	Active, not recruiting	Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients	
		Condition:	Chronic Lymphocytic Leukemia
		Interventions:	Drug: Imiquimod cream; Drug: influenza vaccine
990	Completed	Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)	
		Conditions:	Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
		Interventions:	Biological: GSK580299 (Cervarix™); Biological: Engerix-B™
991	Completed	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: muromonab-CD3; Biological:
992	Recruiting	A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer	
		Condition:	Medullary Thyroid Cancer

993	Active, not recruiting	Intervention:	Biological: GI-6207
		Autologous Vaccine for Follicular Lymphoma	
		Condition:	Lymphoma, Follicular
994	Completed	Intervention:	Biological: Autologous FL vaccine
		A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells	
		Condition:	Renal Cell Carcinoma
995	Completed	Intervention:	Biological: Electrofusion DC vaccine
		Vaccine Therapy in Treating Patients With Melanoma	
		Condition:	Melanoma (Skin)
996	Completed	Interventions:	Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: tyrosinase peptide
		Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females	
		Condition:	Prophylaxis HPV-16/18 Infections and Cervical Neoplasia
997	Completed	Interventions:	Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine; Biological: MEDI-517 HPV-16/18 VLP vaccine with Al(OH) ₃ ; Biological: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
		Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females	
		Condition:	Prophylaxis HPV-16/18 Infections and Cervical Neoplasia
998	Recruiting	Interventions:	Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1); Biological: MEDI-517 HPV-16/18 VLP AS04
		Study of Gardasil in Mid-Adult Males (MAM)	
		Condition:	Human Papillomavirus
999	Completed	Intervention:	Biological: Gardasil
		Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
1000	Active, not recruiting	Interventions:	Biological: MART-1 antigen; Biological: aldesleukin; Biological: gp100 antigen
		Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients	
		Condition:	Transplant
1001	Completed	Intervention:	Biological: Human papillomavirus quadrivalent vaccine
		Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission	
		Condition:	Leukemia
1002	Active, not recruiting	Intervention:	Biological: therapeutic autologous dendritic cells
		Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV	
		Conditions:	Malignant Melanoma Stage III; Malignant Melanoma Stage IV
1003	Recruiting	Intervention:	Biological: TriMix-DC and ipilimumab
		Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients	
		Condition:	Malignant Melanoma
1004	Completed	Intervention:	Drug: Chemotherapy: Temozolomide
		Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase	
		Conditions:	Leukemia, Myeloid, Chronic; Leukemia, Myeloid, Philadelphia-Positive

		Intervention: Biological: Heat Shock Protein 70 HSP70
1005	Completed	Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
		Condition: Prostate Cancer
		Interventions: Procedure: diagnostic procedure; Procedure: molecular diagnostic method; Procedure: protein expression
1006	Not yet recruiting	Dendritic Cell Activating Scaffold in Melanoma
		Condition: Melanoma
		Intervention: Biological: WDVAX
1007	Completed	Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
		Condition: Prostatic Cancer
		Intervention: Biological: Autologous dendritic cell
1008	Completed	Vaccine Therapy in Treating Patients With Metastatic Melanoma
		Condition: Melanoma (Skin)
		Interventions: Biological: MART-1 antigen; Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's
1009	Recruiting	Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
		Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin
		Interventions: Biological: aldesleukin; Other: laboratory biomarker analysis; Radiation: radiation therapy; Biological:
1010	Completed	Dendritic Cell Based Therapy of Renal Cell Carcinoma
		Condition: Advanced Renal Cell Carcinoma
		Intervention: Biological: tumor antigen loaded autologous dendritic cells
1011	Active, not recruiting	CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
		Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
		Interventions: Biological: APC8015 vaccine/bevacizumab; Drug: bevacizumab/temsirolimus
1012	Completed	Biological Therapy in Treating Patients With Prostate Cancer
		Condition: Prostate Cancer
		Interventions: Biological: aldesleukin; Biological: gene-modified tumor cell vaccine therapy; Biological: recombinant interferon
1013	Completed	Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
		Condition: Carcinoma, Renal Cell
		Interventions: Biological: TroVax® (Immunological Vaccine Therapy); Drug: Interferon-alpha
1014	Withdrawn	Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
		Condition: CHRONIC LYMPHOCYTIC B-LEUKEMIA
		Interventions: Biological: IL-2 secreting and hCL4OL-expressing autologous B-CLL cells; Biological: IL-2; Biological: CD40L;
1015	Completed	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
		Condition: Melanoma (Skin)
		Interventions: Biological: aldesleukin; Biological: gp209-2M antigen; Biological: incomplete Freund's adjuvant
1016	Recruiting	Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
		Condition: Systemic Lupus Erythematosus
		Intervention: Drug: Gardasil
1017	Completed	Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
		Conditions: Lymphoma; Multiple Myeloma; Myeloproliferative Disease
		Intervention: Biological: Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived from the A/california/7/2009 (H1N1) virus

1018	Completed	Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.	
	Has	Conditions:	HPV-16/18 Infections and Associated Cervical Neoplasia.; Papillomavirus Vaccines
		Intervention:	Biological: Cervarix
1019	Unknown †	Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to	
		Conditions:	Melanoma (Skin); Metastatic Cancer
		Interventions:	Drug: imiquimod; Drug: indocyanine green solution; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis
1020	Recruiting	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients	
		Condition:	Cutaneous Melanoma
		Interventions:	Biological: CSF470 vaccine, BCG, Molgramostim; Drug: interferon alpha 2b
1021	Recruiting	A Phase I Trial of Safety and Immunogenicity of Gardasil(Registered Trademark) Vaccination Post Stem Cell Transplantation in Patients With	
		Conditions:	Gardasil Vaccine; Stem Cell Transplant; Immunogenicity; Quadrivalent HPC Vaccine; Healthy Volunteers
		Intervention:	Biological: Gardasil
1022	Recruiting	Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China	
		Conditions:	Human Papilloma Virus; Cervical Cancer; Cervical Intraepithelial Neoplasia
		Intervention:	
1023	Completed	Peptide Vaccination for Patients at High Risk for Recurrent Melanoma	
	Has	Condition:	Melanoma
		Interventions:	Drug: Glycoprotein 100 (GP100): 209-217 (210M); Drug: Interleukin-2 (IL-2); Drug: Montanide ISA 51; Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35; Drug: 27-35 (27L): melanoma antigen recognized by
1024	Active, not recruiting	Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors	
		Condition:	Tumors, Central Nervous System
		Intervention:	Biological: Montanide
1025	Unknown †	Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen
1026	Recruiting	Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides	
		Conditions:	Neuroblastoma; Ewing's Sarcoma; Wilm's Tumor; Retinoblastoma; Glioma
		Intervention:	Drug: racotumomab
1027	Completed	Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma	
	Has	Condition:	High-Risk Melanoma
		Interventions:	Drug: gp100:209-217 (210M); Drug: Montanide ISA-51; Drug: Imiquimod
1028	Completed	Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3	
		Condition:	Papillomavirus Infections
		Intervention:	Biological: VGX-3100
1029	Withdrawn	Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination	
		Condition:	Healthy, no Evidence of Disease
		Interventions:	Biological: hepatitis B antigen peptide; Other: placebo; Other: immunoenzyme technique
1030	Recruiting	Study of MAGe-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma	
		Condition:	Multiple Myeloma

1031	Recruiting	Interventions:	Biological: MAGE-A3; Biological: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
			Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
		Conditions:	Human Papillomavirus Infection; Cervical Neoplasia
1032	Enrolling by invitation	Interventions:	Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
			The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
		Conditions:	HIV Positive; Anal Condylomata; Anal Warts; HIV Infections
1033	Completed	Interventions:	Drug: Saline; Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
			A Study of OncoVEXGM-CSF in Stage IIIc and Stage IV Malignant Melanoma
		Condition:	Melanoma
1034	Unknown †	Interventions:	Genetic: Oncolytic viral vector; Procedure: Vaccine Therapy; Procedure: Immune-modulator therapy
			Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
		Condition:	Non-Small Cell Lung Cancer
1035	Recruiting	Interventions:	Biological: Recombinant DNA- pVAX/L523S; Biological: Recombinant adenovirus- Ad/L523S
			Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
		Condition:	Advanced Non-small Cell Lung Cancer
1036	Completed	Interventions:	Biological: racotumomab; Other: Best support treatment
			Acceptance of Human Papillomavirus Vaccination in Postpartum Women
		Conditions:	Human Papilloma Virus; HPV; Post Partum
1037	Active, not recruiting	Intervention:	
			Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
		Condition:	Tumors
1038	Active, not recruiting	Interventions:	Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod; Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
			Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
		Condition:	Pancreas, Adenocarcinoma
1039	Not yet recruiting	Intervention:	Biological: Biological/Vaccine: BC-819
			Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
		Conditions:	Adenocarcinoma of the Prostate; Bone Metastases; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Soft Tissue Metastases; Stage IV Prostate Cancer
1040	Completed	Interventions:	Biological: sipuleucel-T; Radiation: external beam radiation therapy; Other: laboratory biomarker analysis
			Vaccination of Patients With Stage IV Melanoma With Dendritic Cells
		Conditions:	Melanoma; Neoplasm Metastasis
1041	Completed	Intervention:	Biological: Dendritic cell vaccination
			Vaccine Therapy in Treating Patients With Metastatic Melanoma
		Condition:	Melanoma (Skin)
1042	Recruiting	Interventions:	Biological: MART-1 antigen; Biological: filgrastim; Biological: flu matrix peptide p58-66; Biological: gp100
			Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
		Conditions:	Colorectal Carcinoma; Hepatic Metastasis
		Intervention:	Drug: Dendritic cells vaccine

1043	Recruiting	L-BLP25 (Stimuvax) in Prostate Cancer	
		Condition:	Prostate Cancer
1044	Completed	Cytomegalovirus Vaccine in Healthy Participants	
		Condition:	Precancerous/Nonmalignant Condition
1045	Active, not recruiting	Drug Use Investigation for Cervarix®	
		Intervention:	Biological: CMVpp65-A*0201 peptide vaccine
1046	Active, not recruiting	A Study of the Safety, Tolerability, and Immunogenicity of V503 Administered to 9- to 15-Year-Old Japanese Girls (V503-008)	
		Condition:	Papillomavirus Infections
1047	Suspended	A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in	
		Condition:	Metastatic Pancreatic Carcinoma
1048	Recruiting	Study of Gene Modified Immune Cells in Patients With Advanced Melanoma	
		Interventions:	Radiation: tumoral irradiation; Biological: Dendritic cell vaccination; Biological: Additional cycles
1049	Active, not recruiting	A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma	
		Condition:	Nasopharyngeal Carcinoma
1050	Completed	Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)	
		Interventions:	Biological: VCL-CB01; Other: Phosphate-buffered Saline (PBS)
1051	Recruiting	Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma	
		Interventions:	Drug: cyclophosphamide; Biological: Mature dendritic cell vaccine
1052	Completed	Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response	
		Intervention:	Biological: injection of mouse TYRP2 DNA
1053	Recruiting	Home Human Papillomavirus or Pap Exam (HOPE) Study	
		Intervention:	Procedure: Self-collected at home HPV testing
1054	Completed	Dendritic Cell Vaccination During Lymphoid Reconstruction	
		Interventions:	Biological: Autologous Dendritic Cells (DC); Drug: Fludarabine; Biological: Autologous Lymphocyte Infusion (ALI)
1055	Recruiting	Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study	
		Condition:	Human Papillomavirus Infection